GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (FRA:CN2) » Definitions » Cyclically Adjusted PB Ratio

Catalyst Pharmaceuticals (FRA:CN2) Cyclically Adjusted PB Ratio : 10.01 (As of May. 26, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Catalyst Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-26), Catalyst Pharmaceuticals's current share price is €14.515. Catalyst Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €1.45. Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 10.01.

The historical rank and industry rank for Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:CN2' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.79   Med: 9.16   Max: 19.49
Current: 10.25

During the past years, Catalyst Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 19.49. The lowest was 4.79. And the median was 9.16.

FRA:CN2's Cyclically Adjusted PB Ratio is ranked worse than
90.05% of 653 companies
in the Biotechnology industry
Industry Median: 1.73 vs FRA:CN2: 10.25

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Catalyst Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was €4.376. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.45 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Catalyst Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.46 5.55 8.36 17.19 11.89

Catalyst Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.19 10.65 8.72 11.89 10.30

Competitive Comparison of Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Catalyst Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=14.515/1.45
=10.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catalyst Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Catalyst Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=4.376/131.7762*131.7762
=4.376

Current CPI (Mar. 2024) = 131.7762.

Catalyst Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.451 100.560 0.591
201409 0.423 100.428 0.555
201412 0.414 99.070 0.551
201503 0.751 99.621 0.993
201506 0.681 100.684 0.891
201509 0.653 100.392 0.857
201512 0.615 99.792 0.812
201603 0.548 100.470 0.719
201606 0.498 101.688 0.645
201609 0.461 101.861 0.596
201612 0.449 101.863 0.581
201703 0.395 102.862 0.506
201706 0.358 103.349 0.456
201709 0.312 104.136 0.395
201712 0.667 104.011 0.845
201803 0.603 105.290 0.755
201806 0.593 106.317 0.735
201809 0.535 106.507 0.662
201812 0.434 105.998 0.540
201903 0.441 107.251 0.542
201906 0.544 108.070 0.663
201909 0.687 108.329 0.836
201912 0.763 108.420 0.927
202003 0.872 108.902 1.055
202006 0.955 108.767 1.157
202009 1.283 109.815 1.540
202012 1.343 109.897 1.610
202103 1.446 111.754 1.705
202106 1.520 114.631 1.747
202109 1.637 115.734 1.864
202112 1.777 117.630 1.991
202203 1.942 121.301 2.110
202206 2.221 125.017 2.341
202209 2.621 125.227 2.758
202212 2.694 125.222 2.835
202303 2.942 127.348 3.044
202306 3.253 128.729 3.330
202309 3.064 129.860 3.109
202312 3.320 129.419 3.380
202403 4.376 131.776 4.376

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Catalyst Pharmaceuticals  (FRA:CN2) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Catalyst Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Pharmaceuticals (FRA:CN2) Business Description

Traded in Other Exchanges
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceuticals (FRA:CN2) Headlines

No Headlines